Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
MELBOURNE, Australia and NEW YORK, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that it will present at the 34th Annual J. P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 13, 2016, at 3.30 p.m. PST/10.30am Thursday, January 14, 2016 (AEDT).
A live webcast of Mesoblast’s presentation can be accessed via either http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=19955 or http://investorsmedia.mesoblast.com
The archived webcast will be available in the Events and Presentations section of the Company's website via www.mesoblast.com.
About Mesoblast
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) is a global leader in cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases where there are highly unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncology/hematology conditions.
For further information, please contact: Julie Meldrum Global Head of Corporate Communications Mesoblast Limited T: +61 3 9639 6036 E: [email protected]
